TY - JOUR
T1 - KDIGO Controversies Conference on onco-nephrology
T2 - understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
AU - Porta, Camillo
AU - Bamias, Aristotelis
AU - Danesh, Farhad R.
AU - Dębska-Ślizień, Alicja
AU - Gallieni, Maurizio
AU - Gertz, Morie A.
AU - Kielstein, Jan T.
AU - Tesarova, Petra
AU - Wong, Germaine
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Małyszko, Jolanta
AU - Abu-Alfa, Ali K.
AU - Amer, Hatem
AU - Beutel, Gernot
AU - Chapman, Jeremy
AU - Chen, Xiaohong
AU - Chudek, Jerzy
AU - Cosmai, Laura
AU - Danesi, Romano
AU - De Stefano, Filippo
AU - Iseki, Kunitoshi
AU - Jaimes, Edgar A.
AU - Jhaveri, Kenar D.
AU - Jurczyszyn, Artur
AU - Kazancioğlu, Rümeyza
AU - Kitchlu, Abhijat
AU - Kollmannsberger, Christian
AU - Lahoti, Amit
AU - Li, Yang
AU - Macía, Manuel
AU - Matsubara, Takeshi
AU - Mitropoulos, Dionysios
AU - Noiri, Eisei
AU - Perazella, Mark A.
AU - Ronco, Pierre
AU - Rosner, Mitchell H.
AU - Soler Romeo, Maria Jose
AU - Sprangers, Ben
AU - Stadler, Walter M.
AU - Stevens, Paul E.
AU - ladimír Tesař, Tesař
AU - Torres da Costa e Silva, Verônica
AU - Vesole, David H.
AU - Vijayan, Anitha
AU - Viklický, Ondřej
AU - Workeneh, Biruh T.
AU - Yanagita, Motoko
AU - Zakharova, Elena
N1 - Funding Information:
CP declared having consultancy fees from AstraZeneca, Bristol Myers Squibb (BMS), Eisai, EUSA, Ipsen, Merck Serono, Merck Sharp & Dohme (MSD), Novartis, and Pfizer; stock from DNA; and research support from AstraZeneca, BMS, Eisai, EUSA, GE, Ipsen, Merck Serono, MSD, Novartis, and Pfizer; and CP was an expert witness for DNA. AB declared having received consultancy fees from BMS, MSD, Pfizer, and Roche; speaker honoraria from BMS and MSD; and research support from BMS and Pfizer. FRD declared having received research support from National Institutes of Health. MG declared having received speaker honoraria from General Electric. MAG declared having received consultancy fees from Abbvie, Alnylam, Amgen, Annexon, Appellis, Celgene, Janssen, Medscape, Physicians’ Education Resource, Prothena, Research to Practice, Sanofi, and Spectrum; stock options from Aurora Bio; speaker honoraria from Akcea, Johnson and Johnson, and Teva; and research support from National Institutes of Health and Spectrum. JTK declared having received consultancy fees from Amgen and Vifor Pharma; stock from Chemocentryx; speaker honoraria from ExThera Medical and Vifor Pharma; and grants from ExThera Medical; and JTK was an expert witness in vaccine injury cases trialed at the US Federal Court of Claims. PT declared having received consultancy fees from AstraZeneca, Eli Lilly, Novartis, Pfizer, Pierre Fabre, and Roche; and speaker honoraria from AstraZeneca, Eli Lilly, Novartis, Pfizer, Pierre Fabre, and Roche. GW declared having received research support from the National Health and Medical Research Council. DCW declared having received consultancy fees from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Mundipharma, Napp, and Vifor Fresenius Medical Care Renal Pharma; and speaker’s honoraria from Amgen, Astellas, AstraZeneca, Mundipharma, Napp, Pharmacosmos, and Vifor Fresenius Medical Care Renal Pharma. WCW declared having consultancy fees from Akebia, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Relypsa, and Vifor Fresenius Medical Care Renal Pharma. JM declared having consultancy fees from Fresenius Medical Care and Vifor Pharma. All the other authors declared no competing interests.
Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Amgen, Akebia Therapeutics, Boehringer Ingelheim, Fresenius Medical Care, GE Healthcare, and MediBeacon. We thank Jennifer King, PhD, for assistance with manuscript preparation. The conference agenda, discussion questions, and plenary session presentations are available on the KDIGO website: https://kdigo.org/conferences/onco-nephrology-conference/.
Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Amgen, Akebia Therapeutics, Boehringer Ingelheim, Fresenius Medical Care, GE Healthcare, and MediBeacon. We thank Jennifer King, PhD, for assistance with manuscript preparation. The conference agenda, discussion questions, and plenary session presentations are available on the KDIGO website: https://kdigo.org/conferences/onco-nephrology-conference/ .
Publisher Copyright:
© 2020 Kidney Disease:Improving Global Outcomes (KDIGO)
PY - 2020/11
Y1 - 2020/11
N2 - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues in the setting of malignancy can worsen patient outcomes and diminish the adequacy of anticancer treatments. In addition, the oncology treatment landscape is changing rapidly, and data on tolerability of novel therapies in patients with CKD are often lacking. Caring for oncology patients has become more specialized and interdisciplinary, currently requiring collaboration among specialists in nephrology, medical oncology, critical care, clinical pharmacology/pharmacy, and palliative care, in addition to surgeons and urologists. To identify key management issues in nephrology relevant to patients with malignancy, KDIGO (Kidney Disease: Improving Global Outcomes) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology in December 2018. This report covers issues related to kidney impairment and solid organ malignancies as well as management and treatment of kidney cancer. Knowledge gaps, areas of controversy, and research priorities are described.
AB - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues in the setting of malignancy can worsen patient outcomes and diminish the adequacy of anticancer treatments. In addition, the oncology treatment landscape is changing rapidly, and data on tolerability of novel therapies in patients with CKD are often lacking. Caring for oncology patients has become more specialized and interdisciplinary, currently requiring collaboration among specialists in nephrology, medical oncology, critical care, clinical pharmacology/pharmacy, and palliative care, in addition to surgeons and urologists. To identify key management issues in nephrology relevant to patients with malignancy, KDIGO (Kidney Disease: Improving Global Outcomes) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology in December 2018. This report covers issues related to kidney impairment and solid organ malignancies as well as management and treatment of kidney cancer. Knowledge gaps, areas of controversy, and research priorities are described.
KW - glomerular filtration rate
KW - nephrotoxicity
KW - oncology
KW - renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85093980957&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.06.046
DO - 10.1016/j.kint.2020.06.046
M3 - Article
C2 - 33126977
AN - SCOPUS:85093980957
SN - 0085-2538
VL - 98
SP - 1108
EP - 1119
JO - Kidney International
JF - Kidney International
IS - 5
ER -